Stock Analiz

Xeris Biopharma Holdings, Inc. (XERS) financials: revenue, earnings and cash flow

Fiscal 2020–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Xeris Biopharma’s revenue went from $20M in fiscal 2020 to $292M in fiscal 2025, growth of about 70.2% a year.

Net income in fiscal 2025 was $554000, a net margin of 0.2%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $368M and net income -$6M.

The diluted share count rose 305% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $20M20202021: $50M20212022: $110M20222023: $164M20232024: $203M20242025: $292M2025$292M
Net income
2020: -$91M20202021: -$123M20212022: -$95M20222023: -$62M20232024: -$55M20242025: $5540002025$554000
EPS (diluted)
2020: $-2.1420202021: $-1.5520212022: $-0.7020222023: $-0.4520232024: $-0.3720242025: $0.002025$0.00

Income statement

Fiscal yearTTM202520242023202220212020
Revenue$368M$292M$203M$164M$110M$50M$20M
Gross profit———————
Operating income$47M$25M-$34M-$44M-$82M-$115M-$84M
Net income-$6M$554000-$55M-$62M-$95M-$123M-$91M
EPS (diluted)$-0.04$0.00$-0.37$-0.45$-0.70$-1.55$-2.14
R&D$38M$31M$26M$22M$21M$25M$21M
Revenue growth—+43.7%+23.9%+48.7%+122.3%+142.7%—

Cash flow

Fiscal yearTTM202520242023202220212020
Operating cash flow$74M$29M-$37M-$47M-$103M-$96M-$81M
Capital spending-$1M————-$1M-$377000
Free cash flow$73M————-$97M-$81M
Dividends paid—$0$0$0$0$0$0
Buybacks———————
Stock-based pay$31M$22M$18M$11M$12M$11M$8M

Balance sheet

Fiscal yearTTM202520242023202220212020
Cash—$111M$72M$72M$122M$102M$134M
Debt—$258M$271M$229M$198M$88M$87M
Equity—$14M-$30M-$7M$45M$95M$34M
Total assets—$384M$323M$323M$345M$304M$159M
Shares (diluted)190M173M147M138M136M79M43M

Margins and returns

Fiscal yearTTM202520242023202220212020
Gross margin———————
Operating margin12.7%8.5%-16.6%-26.9%-74.3%-232.2%-408.8%
Net margin-1.8%0.2%-27.0%-38.0%-85.9%-247.5%-446.0%
FCF margin19.7%————-194.8%-396.1%
ROIC—9.2%-13.4%-19.4%-33.2%-62.8%-54.6%
ROE—4.0%185.2%917.9%-209.5%-128.9%-270.0%

Frequently asked questions

What is Xeris Biopharma’s annual revenue?

$292M in fiscal 2025 and $368M over the twelve months to September 30, 2026.

How much profit does Xeris Biopharma make?

Net income was $554000 in fiscal 2025 (net margin 0.2%).

Is Xeris Biopharma’s revenue growing?

Yes: revenue rose 43.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.